The past twelve months have seen an unprecedented level of excitement, investment, and progression within the gene therapy for muscular disorders field. As the industry endeavours to move gene therapy treatment through the preclinical and clinical pipeline, in context of reducing toxicity and increasing efficacy, attending the 3rd Annual Gene Therapy for Muscular Disorders Summit has never been so crucial.
This year's summit will return to Boston to reunite 100+ leading experts in biotech, pharma and academia to continue to develop strategies to deliver safer and more effective gene therapies to muscle cells.
This summit will encompass all aspects of preclinical development and highlight the obstacles in clinical trials, enabling you to address and overcome these challenges.
Speakers: Adam Cockrell, Senior Director of Vector Biology, AavantiBio, Alex Murphy, Senior Medical Director, Roche, Beatrice Darimont, Chief Scientific Officer, Cytoo, Bradley Hodges, Partner, CureDuchenne, Catja Freiburghaus, Senior Scientist, Hansa Biopharma, Daniel Fitzgerald, Project Manager for LGMD Program, AskBio, Dorota Gruber, Assistant Chief, Pediatric Cardiogenomics, Cohen Children's Medical Center, Genine Winslow, Chief Executive Officer and Founder, Chameleon Biosciences, Glen Banks, Senior Principal Scientist, Bristol Myers Squibb, Gor Sarkisyan, Chief Scientific Officer, GrittGene, Isin Dalkilic-Liddle, Director, Head of Rare Genetic Diseases Group, Orna Therapeutics, Kathy Ivey, VP Gene, Therapy Research, Tenaya Therapeutics, Leah Sabin, Director - Viral Vector Technologies, Regeneron, Mike Stec, Staff Scientist, Regeneron, Nicolas Christoforou, Rare Cardiac and Neuromuscular Disorders, Rare Disease Research Unit, Pfizer, Ranjan Batra SVP, Research and Development, LocanaBio, Inc., Ravi Iyer, Chief Scientific Officer, Script Biosciences, Rodney Howell, Professor and Chairman of Pediatrics Emeritus, University of Miami, Serge Braun, Director - Scientific and Neuromuscular Strategy, Genethon, Sharon McGonigle, Senior Director R and D, Solid Biosciences
This year's summit will return to Boston to reunite 100+ leading experts in biotech, pharma and academia to continue to develop strategies to deliver safer and more effective gene therapies to muscle cells.
This summit will encompass all aspects of preclinical development and highlight the obstacles in clinical trials, enabling you to address and overcome these challenges.
Speakers: Adam Cockrell, Senior Director of Vector Biology, AavantiBio, Alex Murphy, Senior Medical Director, Roche, Beatrice Darimont, Chief Scientific Officer, Cytoo, Bradley Hodges, Partner, CureDuchenne, Catja Freiburghaus, Senior Scientist, Hansa Biopharma, Daniel Fitzgerald, Project Manager for LGMD Program, AskBio, Dorota Gruber, Assistant Chief, Pediatric Cardiogenomics, Cohen Children's Medical Center, Genine Winslow, Chief Executive Officer and Founder, Chameleon Biosciences, Glen Banks, Senior Principal Scientist, Bristol Myers Squibb, Gor Sarkisyan, Chief Scientific Officer, GrittGene, Isin Dalkilic-Liddle, Director, Head of Rare Genetic Diseases Group, Orna Therapeutics, Kathy Ivey, VP Gene, Therapy Research, Tenaya Therapeutics, Leah Sabin, Director - Viral Vector Technologies, Regeneron, Mike Stec, Staff Scientist, Regeneron, Nicolas Christoforou, Rare Cardiac and Neuromuscular Disorders, Rare Disease Research Unit, Pfizer, Ranjan Batra SVP, Research and Development, LocanaBio, Inc., Ravi Iyer, Chief Scientific Officer, Script Biosciences, Rodney Howell, Professor and Chairman of Pediatrics Emeritus, University of Miami, Serge Braun, Director - Scientific and Neuromuscular Strategy, Genethon, Sharon McGonigle, Senior Director R and D, Solid Biosciences
